Latest filingAug 28, 2026Most recent Form 4
ARQT
Arcutis Biotherapeutics, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$115M5 sells
Net open-market-$115M3 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period17transactions
- M · Option exercise · dominant12 · 71%
- S · Open-market sells5 · 29%
Activity by reported role
A joint filing can contribute to multiple roles17transactions
- Director · dominant16 · 94%
- SR1 · 6%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (3)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeCurran TerrieCommon Stock · Direct
34,674Aug 27, 2026
Welgus Howard G.Common Stock · Direct
41,205Aug 17, 2026
Welgus Howard G.Stock Option (right to buy) · Direct
20,287Aug 17, 2026
Curran TerrieStock Option (right to buy) · Direct
0Aug 27, 2026
Burnett PatrickCommon Stock · Direct
117,592Aug 19, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 03 → Sep 03
LessMore
Top insiders
By absolute net value across the selected period- WG-$123.8k
- BP-$45.8k
- CT-$27.9k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
ARQT transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| ARQT | Curran Terrie | DIR | sale | 1.07k | -$2.79M | S | +0.2% | 08/24 | 08/20 | |
| ARQT | Burnett Patrick | SR | sale | 1.69k | -$4.58M | S | −5.2% | 08/21 | 08/19 | |
| ARQT | Welgus Howard G. | DIR | sale10b5-1 | 4.73k | -$12.3M | S | −10.2% | 08/19 | 08/17 |
Arcutis Biotherapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Arcutis Biotherapeutics, Inc.?
Curran Terrie, Burnett Patrick, Welgus Howard G..
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Curran Terrie reported a sale on Aug 27, 2026 valued at $67.7M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $1,153,689.10. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.